ArticleNature immunology2018

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.

Amira A Barkal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.